Novel Biomarkers for Evaluation of Endothelial Dysfunction

Leite, Ana Rita; Borges‐Canha, Marta; Cardoso, Rita Alves de Almeida; Neves, João Sérgio; Castro‐Ferreira, Ricardo; Leite‐Moreira, Adelino

doi:10.1177/0003319720903586

Cited by 121 publications

(109 citation statements)

References 155 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with cardiac ischemia, circulating EMPs correlate positively with the disease severity and inversely with endothelial function assessed by FMD [86]. Endoglin or CD105 [87][88][89], a receptor for transforming growth factor beta (TGF-β), and Endocan, a soluble proteoglycan secreted by vascular endothelial cells [90], are additional putative biomarkers of ED. Among all biomarkers of ED, ADMA is perhaps the most accepted marker of ED.…”

Section: Biomarkers Of Endothelial Biologymentioning

confidence: 99%

Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update

Roumeliotis

Mallamaci

Zoccali

2020

JCM

174

128

View full text Add to dashboard Cite

The vascular endothelium is a dynamic, functionally complex organ, modulating multiple biological processes, including vascular tone and permeability, inflammatory responses, thrombosis, and angiogenesis. Endothelial dysfunction is a threat to the integrity of the vascular system, and it is pivotal in the pathogenesis of atherosclerosis and cardiovascular disease. Reduced nitric oxide (NO) bioavailability is a hallmark of chronic kidney disease (CKD), with this disturbance being almost universal in patients who reach the most advanced phase of CKD, end-stage kidney disease (ESKD). Low NO bioavailability in CKD depends on several mechanisms affecting the expression and the activity of endothelial NO synthase (eNOS). Accumulation of endogenous inhibitors of eNOS, inflammation and oxidative stress, advanced glycosylation products (AGEs), bone mineral balance disorders encompassing hyperphosphatemia, high levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23), and low levels of the active form of vitamin D (1,25 vitamin D) and the anti-ageing vasculoprotective factor Klotho all impinge upon NO bioavailability and are critical to endothelial dysfunction in CKD. Wide-ranging multivariate interventions are needed to counter endothelial dysfunction in CKD, an alteration triggering arterial disease and cardiovascular complications in this high-risk population.

show abstract

Section: Biomarkers Of Endothelial Biologymentioning

confidence: 99%

Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update

Roumeliotis

Mallamaci

Zoccali

2020

JCM

174

128

View full text Add to dashboard Cite

show abstract

“…For these reasons, circulating biomarkers are complementary and promising tools. So far, numerous studies have been conducted considering traditional, also defined “classic”, endothelial circulating markers, including soluble adhesion molecules, such as E-selectin, ICAM-1, and VCAM-1, as well as molecules involved in the coagulation pathway, in particular von Willebrand factor (vWF) and soluble thrombomodulin, and also inflammatory markers such as interleukins IL-6, IL-8, and IL-12 and high-sensitivity C-reactive protein (hsCRP) [ 37 – 39 ].…”

Section: Introductionmentioning

confidence: 99%

“…Interestingly, it has been proposed that EVs from endothelial, but not those from other cellular origin, could be very useful for stratifying cardiovascular risk and for monitoring disease activity, severity, and the effectiveness of atheroprotective treatments [ 37 , 40 – 42 ].…”

Section: Introductionmentioning

confidence: 99%

Role of Polyphenols and Carotenoids in Endothelial Dysfunction: An Overview from Classic to Innovative Biomarkers

Pietro

Baldassarre

Cichelli

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Nowadays, the dramatically increased prevalence of metabolic diseases, such as obesity and diabetes mellitus and their related complications, including endothelial dysfunction and cardiovascular disease, represents one of the leading causes of death worldwide. Dietary nutrients together with healthy lifestyles have a crucial role in the endothelium health-promoting effects. From a growing body of evidence, active natural compounds from food, including polyphenols and carotenoids, have attracted particular attention as a complementary therapy on atherosclerosis and cardiovascular disease, as well as preventive approaches through the attenuation of inflammation and oxidative stress. They mainly act as radical scavengers by promoting a variety of biological mechanisms, such as improvements in endothelial function, blood pressure, platelet activity, and insulin sensitivity, and by modulating various known biomarkers. The present review highlights the role of polyphenols and carotenoids in early endothelial dysfunction with attention to their beneficial effect in modulating both classical and recent technologically generated emerging biomarkers. These, alone or in combination, can play an important role in the prediction, diagnosis, and evolution of cardiovascular disease. However, a main challenge is to speed up early and prompt new interventions in order to prevent or slow down disease progression, even with an adequate intake of bioactive compounds. Hence, there is an urgent need of new more validated, appropriate, and reliable diagnostic and therapeutic biomarkers useful to diagnose endothelial dysfunction at an earlier stage.

show abstract

“…Endocan is a marker of ED, inflammation, and atherosclerosis. 18 Increased levels were reported in cardiovascular diseases 19 and patients with erectile dysfunction. 20 Endocan is also a potential inflammatory marker and may reflect ED.…”

Section: Testing Endothelial Functionmentioning

confidence: 99%

Endothelial Function in Patients With Continuous-Flow Left Ventricular Assist Devices

et al. 2020

View full text Add to dashboard Cite

The endothelium plays a crucial role in maintaining cardiovascular homeostasis. Shear stress generated by flowing blood regulates the release of substances that provide adequate tissue perfusion. The extent of damage to endothelial cells depends on locally disturbed shear stress caused by the deteriorated flow. Patients with heart failure have reduced cardiac output, which results in reduced blood flow and negative shear stress. Reduced shear stress also affects microcirculation and reduces tissue perfusion. Consequently, the production of free oxygen radicals is increased and bioavailability of nitric oxide is additionally decreased. Therefore, endothelial dysfunction is involved in the progression of heart failure and cardiovascular events. Left ventricular assist devices (LVAD) are used for the treatment of patients with advanced heart failure. Older pulsatile flow LVADs were mostly substituted by continuous-flow LVADs (cf-LVADs). Despite the advantages of the cf-LVADs, the loss of pulsatility leads to different complications on the micro- and macrovascular levels. One of the pathogenetic mechanisms of cardiovascular complications with cf-LVADs may be endothelial dysfunction, which after the implantation of the device does not improve and may even deteriorate. In contrast, the pulsatile pattern of LVADs on blood flow could preserve endothelial function.

show abstract

Novel Biomarkers for Evaluation of Endothelial Dysfunction

Cited by 121 publications

References 155 publications

Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update

Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update

Role of Polyphenols and Carotenoids in Endothelial Dysfunction: An Overview from Classic to Innovative Biomarkers

Endothelial Function in Patients With Continuous-Flow Left Ventricular Assist Devices

Contact Info

Product

Resources

About